Last reviewed · How we verify
Chemotherapy combined with trastuzumab
Chemotherapy drugs kill rapidly dividing cancer cells while trastuzumab (a monoclonal antibody) targets and blocks HER2 receptors on cancer cells to prevent growth and trigger immune destruction.
Chemotherapy drugs kill rapidly dividing cancer cells while trastuzumab (a monoclonal antibody) targets and blocks HER2 receptors on cancer cells to prevent growth and trigger immune destruction. Used for HER2-positive breast cancer (likely primary indication based on trastuzumab use), HER2-positive gastric or gastroesophageal junction cancer (possible indication).
At a glance
| Generic name | Chemotherapy combined with trastuzumab |
|---|---|
| Also known as | Capecitabine, Vinorelbine, Gemcitabine, trastuzumab |
| Sponsor | Sun Yat-sen University |
| Drug class | Chemotherapy + monoclonal antibody combination |
| Target | HER2 (human epidermal growth factor receptor 2) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This combination approach uses cytotoxic chemotherapy to damage cancer cell DNA and induce apoptosis, while trastuzumab specifically binds to HER2 (human epidermal growth factor receptor 2) on the surface of HER2-positive cancer cells. Trastuzumab blocks HER2 signaling, prevents cell proliferation, and recruits immune cells to destroy the cancer cells. The synergistic effect enhances anti-tumor activity compared to either agent alone.
Approved indications
- HER2-positive breast cancer (likely primary indication based on trastuzumab use)
- HER2-positive gastric or gastroesophageal junction cancer (possible indication)
Common side effects
- Cardiotoxicity / left ventricular dysfunction
- Neutropenia
- Anemia
- Nausea and vomiting
- Infusion reactions
- Fatigue
Key clinical trials
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma (PHASE3)
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer (PHASE3)
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (PHASE3)
- A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (PHASE1)
- Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer (PHASE3)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
- DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chemotherapy combined with trastuzumab CI brief — competitive landscape report
- Chemotherapy combined with trastuzumab updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI